Thomas Franklin Westbrook
Affiliations: | 2008- | Biochemistry and Molecular Biology | Baylor College of Medicine, Houston, TX |
Area:
cancer research, genetics, technology, therapeuticsWebsite:
https://profiles.viictr.org/display/BCM/thomas-westbrookGoogle:
"Thomas Franklin Westbrook"Bio:
https://www.bcm.edu/people/view/trey-westbrook-ph-d/baylor-college-of-medicine-faculty-graduate-faculty-r-z-biochemistry-and-molecular-biology/b26b8e5c-ffed-11e2-be68-080027880ca6/55b7f1cd-55c8-463b-bd07-22310a591328
https://www.bcm.edu/research/labs/thomas-westbrook
https://scholar.google.com/citations?user=IBOcY8nCwAYC&hl=en
Parents
Sign in to add mentor| Dennis J. McCance | grad student | 1998-2002 | Rochester (Microtree) | |
| (Mislocalization of Cip /Kip CDK inhibitors and dysregulation of cellular proliferation by the HPV16 E7 oncoprotein.) | ||||
| Stephen J. Elledge | post-doc | 2003-2007 | Harvard Medical School (Chemistry Tree) | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cai WL, Chen JF, Chen H, et al. (2022) Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. Elife. 11 |
| Gao Y, Kabotyanski EB, Shepherd JH, et al. (2021) Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Research Communications. 1: 178-193 |
| Einstein JM, Perelis M, Chaim IA, et al. (2021) Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Molecular Cell |
| Krug K, Jaehnig EJ, Satpathy S, et al. (2020) Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell |
| Arnal-Estapé A, Cai WL, Albert AE, et al. (2020) Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6. Oncogene |
| Gao Y, Kabotyanski E, Acosta D, et al. (2020) Abstract P4-08-01: Tumor suppressor PLK2 may serve as a biomarker in triple negative breast cancer for combinational therapy of PLK1 inhibitors with the standard-of-care chemotherapy Cancer Research. 80 |
| Hirukawa A, Singh S, Wang J, et al. (2019) Reduction of Global H3K27me Enhances HER2/ErbB2 Targeted Therapy. Cell Reports. 29: 249-257.e8 |
| Kim IS, Gao Y, Welte T, et al. (2019) Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nature Cell Biology |
| Mowery CT, Reyes JM, Cabal-Hierro L, et al. (2018) Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression. Cell Reports. 25: 1898-1911.e5 |
| Rousseaux MWC, Vázquez-Vélez GE, Al-Ramahi I, et al. (2018) A druggable genome screen identifies modifiers of α-synuclein levels via a tiered cross-species validation approach. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience |